Angina Is as Subjective as Any Other Pain

Almost 80% of all patients randomized in this study reported Canadian Cardiovascular Society class II or III angina, and almost all of them (97%) had more than 1 positive non-invasive ischemia test that matched the area of their single diseased coronary vessel. Beyond fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR), the study randomized patients to undergo angioplasty or a sham procedure (placebo group). We might have expected angioplasty patients to resolve their symptoms and placebo patients to continue with the same angina functional class. It should be noted that all patients were symptomatic and they all had single-vessel disease, with ischemia shown in more than one functional study.

Our expectations turned out to be quite different from reality, since almost half the patients who underwent angioplasty continued with angina and, more interestingly, 31.5% of placebo patients (i.e., those who underwent a sham procedure) reported being symptom-free. That is a significant difference, which leads us to conclude that, while angioplasty does actually improve symptoms, some things we are yet to understand.

 

Before randomization, all patients were assessed with iFR and FFR, while results were blinded. Mean FFR was 0.69 ± 0.16 and mean iFR was 0.76±0.22 (undoubtedly, all subjects were ischemic patients) in 196 study patients, among whom 103 underwent angioplasty and 93 underwent a placebo procedure.


Read also: CTO Revascularization Improves Quality of Life.


Angioplasty clearly improved stress echocardiography scores (p < 0.0001) and its effect was progressively more evident with decreasing FFR and iFR (p for interaction < 0.00001). That is the expectable, logical result for this study.

 

However, angioplasty did not improve angina frequency scores significantly more than placebo, and there was no detectable evidence of interaction with FFR (p = 0.849) or iFR (p = 0.783) results.


Read also: Manual vs. Mechanical Compression after Transradial Catheterization.


Despite all of the above, as it was mentioned at the beginning of this article, angioplasty was associated with more freedom from angina (49.5% versus 31.5%; odds ratio [OR]: 2.47; 95% confidence interval [CI]: 1.30 to 4.72; p = 0.006), although neither FFR nor iFR could predict this effect.

 

This is undoubtedly one of the most interesting studies ever published on ischemic heart disease and, despite its scarce 196 patients, it is certainly bound to start a debate.

 

Original title: Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease. Physiology-Stratified Analysis of ORBITA.

Reference: Al-Lamee R et al. Circulation. 2018 May 22. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...